SCHEMBL1369037

SCHEMBL1369037

CS(=O)(=O)c1ccccc1Nc1ccccc1CN(c1cccnc1)c1cccnc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.44
ALK Q9UM73 2/20 0.41
ADRA1A P35348 3/20 0.40
JAK1 P23458 4/20 0.39
TYK2 P29597 4/20 0.39
PTGS2 P35354 2/20 0.39
JAK2 O60674 5/20 0.39
JAK3 P52333 2/20 0.39
PTK2 Q05397 2/20 0.39
ALDH1A1 P00352 3/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1B P35368 1/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KCNH2 Q12809 2/20 0.37
KIT P10721 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369059 0.89 ALK (0.45) PTGS1ALKADRA1AJAK1TYK2
SCHEMBL1368653 0.82 TAAR1 (0.42) ALKJAK1TYK2JAK2JAK3
SCHEMBL1368740 0.80 HCRTR1 (0.40) ALKJAK1TYK2JAK2JAK3
SCHEMBL4977171 0.79 PTK2 (0.39) PTGS1ALKJAK1TYK2PTGS2
SCHEMBL1368614 0.75 KCNA5 (0.45) PTGS1PTGS2PTK2ALDH1A1LMNA
SCHEMBL1370576 0.73 TAAR1 (0.41) ALKADRA1AJAK1TYK2JAK2
SCHEMBL1369281 0.70 TAAR1 (0.37) JAK1TYK2JAK2JAK3PTK2
SCHEMBL30228891 0.69 ALK (0.49) PTGS1ALKADRA1AJAK1TYK2
SCHEMBL884789 0.68 KCNA5 (0.45) ALKADRA1AJAK1TYK2KCNH2
SCHEMBL1368209 0.68 ALDH1A1 (0.40) ADRA1APTK2ALDH1A1ADRA2AADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US claimed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US claimed
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US disclosed
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US disclosed
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US disclosed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
EP-1993551-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-11-26 EP disclosed
WO-2007089735-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004229-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 PTGS1 1533/4885ALK 967/4885ADRA1A 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.